While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

One of the most remarkable aspects of the populist alliance between Robert F. Kennedy Jr. and Donald Trump is that it puts ...

The rapid progress in AI has also facilitated real-life applications within the pharmaceutical industry that may lead to ...

WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

Yuhan Corp. posted record-breaking third-quarter results, with revenue reaching 598.8 billion won and operating profit ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Robert F. Kennedy Jr. has vowed to combat "the chronic disease epidemic in this country" in the Trump administration, with ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

BEIJING -- China has highlighted its commitment to encouraging the long-term operation and development of foreign-funded ...

Drug shortages in the U.S. are increasing in number and duration, primarily affecting generic and multi-sourced drugs that ...

Pharmacy college job fairs propel rapport between academia and industry to create capable workforce: Nandita Vijayasimha, Bengaluru Thursday, November 14, 2024, 08:00 Hrs [IST] Ph ...